P35. Vitamin C does not enhance reprogramming after SCNT

详细信息    查看全文

• 作者：Ah Reum Lee^a ; ^{leopon09@hanmail.net"" rel=""nofollow} ; Keigo Matsubara^a ; Noriyuki Okuyama^a ; Kazuhiro Saeki^a ; Kazuya Matsumoto^a ; Akira Iritani^a ; Teruhiko Wakayama^b ; Satoshi Kishigami^a ; Yoshihiko Hosoi^a
• 刊名：Differentiation
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：80
• 期：Complete
• 页码：S28
• 全文大小：47 K

文摘

Reprogramming of somatic-cell nuclei has been inefficient in both somatic cell nuclear transfer (SCNT) and iPS technologies. Recently, it has been shown that the presence of 10–200 µg/ml vitamin C (Vc) improves efficiency tenfold in generation of induced pluripotent stem (iPS) cells in mice and humans (Esteban et al., 2009). It has been suggested that Vc may overcome the senescence roadblock during the reprogramming process in iPS generation, probably independent of its function as an antioxidant. Currently, this improvement is thought to result from alleviating cell senescence via P53 repression. Furthermore, Vc promotes the transition of pre-iPS cells to a fully reprogrammed state. Here, we examined whether addition of Vc can improve SCNT development. First we tested how addition of Vc to culture media affects parthenogenetic embryonic development. It was found that the presence of 10 mg/ml Vc in parthenogenetic oocyte activation killed all of the oocytes. In contrast, less than 0.1 mg/ml Vc kept embryos viable through preimplantation development with similar blastocyst rates (90 % ), suggesting that the presence of 0.1 mg/ml Vc does not interfere preimplantation development. Next, we applied of 0.1 mg/ml Vc to SCNT embryos in order to improve development. Unfortunately the addition of Vc did not improve, but rather worsened it (39 % vs. 30 % for control and Vc-treated embryos). Finally, we confirmed the expression of p53 during the preimplantation. Taken together, these results indicate that in contrast to iPS generation, inhibition of p53 does not enhance reprogramming of somatic cells in SCNT, suggesting different rate-limiting steps in the reprogramming pathway of these two reprogramming technologies or/and also their different reprogramming mechanisms.